Kymera Therapeutics
KYMR
121 hedge funds and large institutions have $1.39B invested in Kymera Therapeutics in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 48 increasing their positions, 38 reducing their positions, and 21 closing their positions.
219% more call options, than puts
Call options by funds: $30.2M | Put options by funds: $9.44M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
26% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 38
21% more capital invested
Capital invested by funds: $1.15B → $1.39B (+$243M)
5.75% more ownership
Funds ownership: 96.56% → 102.31% (+5.7%)
5% less funds holding
Funds holding: 127 → 121 (-6)
24% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$44.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$31.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.9M |
| 5 |
AG
Artal Group
Luxembourg
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$23.8M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$10.5M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$6.09M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$5.41M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$3.13M |
KYMR Hedge Fund Activity: Q4 2022 in Review
121 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q4 2022, worth a combined $1.39B — up 21% from $1.15B a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of KYMR and 16 opened new positions — a net loss of 5 holders — while 38 trimmed existing stakes and 48 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $44.8M. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $23.8M.
- 121 institutional investors held Kymera Therapeutics (KYMR) as of Q4 2022, down from 127 in Q3 2022.
- Funds reported $1.39B of Kymera Therapeutics stock for Q4 2022, up 21% quarter-over-quarter.
- 16 funds opened new Kymera Therapeutics positions in Q4 2022 and 21 closed out, a net change of -5 holders.
- The largest Kymera Therapeutics buyer in Q4 2022 was Avoro Capital Advisors, an estimated $44.8M added.
- The largest Kymera Therapeutics seller in Q4 2022 was Atlas Venture Life Science Advisors, an estimated $23.8M sold.
Based on aggregated 13F filings for Q4 2022.